Pediatric NAFLD: an overview and recent developments in diagnostics and treatment

Laura Draijer, Marc Benninga, Bart Koot

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children and adults in industrialized countries. Besides liver-related morbidity, NAFLD is also associated with an increased risk of cardiovascular disease, type 2 diabetes and mortality at adult age. However, despite the high prevalence and serious complications, diagnosing and staging of disease remains complicated due to a lack of accurate screening tools and non-invasive methods to detect fibrosis. Areas covered: Recent insights in epidemiology, pathogenesis, diagnostic evaluation and treatment options in pediatric NAFLD are being reviewed, with a particular focus on new developments in diagnostic tools. Expert opinion: Due to their long life span, children with NAFLD are particularly at risk of complications in their lifetime. Therefore, an effective screening strategy for children to identify those with NAFLD at risk of complications is urgently needed. This is further underscored by new pharmacological therapies that are expected to become available in the next 5 years. Momentarily no accurate non-invasive method for diagnosing pediatric NAFLD is available. New promising biomarkers and imaging tools could hopefully provide better screening tools and could contribute to the development of a successful management plan to identify children with NAFLD.
LanguageEnglish
Pages447-461
JournalExpert review of gastroenterology and hepatology
Volume13
Issue number5
DOIs
Publication statusPublished - 2019

Cite this

@article{2f68bc8441bc43439ff742cfb759ee49,
title = "Pediatric NAFLD: an overview and recent developments in diagnostics and treatment",
abstract = "Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children and adults in industrialized countries. Besides liver-related morbidity, NAFLD is also associated with an increased risk of cardiovascular disease, type 2 diabetes and mortality at adult age. However, despite the high prevalence and serious complications, diagnosing and staging of disease remains complicated due to a lack of accurate screening tools and non-invasive methods to detect fibrosis. Areas covered: Recent insights in epidemiology, pathogenesis, diagnostic evaluation and treatment options in pediatric NAFLD are being reviewed, with a particular focus on new developments in diagnostic tools. Expert opinion: Due to their long life span, children with NAFLD are particularly at risk of complications in their lifetime. Therefore, an effective screening strategy for children to identify those with NAFLD at risk of complications is urgently needed. This is further underscored by new pharmacological therapies that are expected to become available in the next 5 years. Momentarily no accurate non-invasive method for diagnosing pediatric NAFLD is available. New promising biomarkers and imaging tools could hopefully provide better screening tools and could contribute to the development of a successful management plan to identify children with NAFLD.",
author = "Laura Draijer and Marc Benninga and Bart Koot",
year = "2019",
doi = "10.1080/17474124.2019.1595589",
language = "English",
volume = "13",
pages = "447--461",
journal = "Expert review of gastroenterology and hepatology",
issn = "1747-4132",
number = "5",

}

Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. / Draijer, Laura; Benninga, Marc; Koot, Bart.

In: Expert review of gastroenterology and hepatology, Vol. 13, No. 5, 2019, p. 447-461.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Pediatric NAFLD: an overview and recent developments in diagnostics and treatment

AU - Draijer, Laura

AU - Benninga, Marc

AU - Koot, Bart

PY - 2019

Y1 - 2019

N2 - Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children and adults in industrialized countries. Besides liver-related morbidity, NAFLD is also associated with an increased risk of cardiovascular disease, type 2 diabetes and mortality at adult age. However, despite the high prevalence and serious complications, diagnosing and staging of disease remains complicated due to a lack of accurate screening tools and non-invasive methods to detect fibrosis. Areas covered: Recent insights in epidemiology, pathogenesis, diagnostic evaluation and treatment options in pediatric NAFLD are being reviewed, with a particular focus on new developments in diagnostic tools. Expert opinion: Due to their long life span, children with NAFLD are particularly at risk of complications in their lifetime. Therefore, an effective screening strategy for children to identify those with NAFLD at risk of complications is urgently needed. This is further underscored by new pharmacological therapies that are expected to become available in the next 5 years. Momentarily no accurate non-invasive method for diagnosing pediatric NAFLD is available. New promising biomarkers and imaging tools could hopefully provide better screening tools and could contribute to the development of a successful management plan to identify children with NAFLD.

AB - Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children and adults in industrialized countries. Besides liver-related morbidity, NAFLD is also associated with an increased risk of cardiovascular disease, type 2 diabetes and mortality at adult age. However, despite the high prevalence and serious complications, diagnosing and staging of disease remains complicated due to a lack of accurate screening tools and non-invasive methods to detect fibrosis. Areas covered: Recent insights in epidemiology, pathogenesis, diagnostic evaluation and treatment options in pediatric NAFLD are being reviewed, with a particular focus on new developments in diagnostic tools. Expert opinion: Due to their long life span, children with NAFLD are particularly at risk of complications in their lifetime. Therefore, an effective screening strategy for children to identify those with NAFLD at risk of complications is urgently needed. This is further underscored by new pharmacological therapies that are expected to become available in the next 5 years. Momentarily no accurate non-invasive method for diagnosing pediatric NAFLD is available. New promising biomarkers and imaging tools could hopefully provide better screening tools and could contribute to the development of a successful management plan to identify children with NAFLD.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85064567710&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30875479

U2 - 10.1080/17474124.2019.1595589

DO - 10.1080/17474124.2019.1595589

M3 - Review article

VL - 13

SP - 447

EP - 461

JO - Expert review of gastroenterology and hepatology

T2 - Expert review of gastroenterology and hepatology

JF - Expert review of gastroenterology and hepatology

SN - 1747-4132

IS - 5

ER -